A Phase III, Multicenter, Collaborative, Open-Label Clinical Trial of Sildenafil in Japanese Patients With Pulmonary Arterial Hypertension

Satoh, Tohru; Saji, Tsutomu; Watanabe, Hiroshi; Ogawa, Satoshi; Takehara, Kazuhiko; Tanabe, Nobuhiro; Yamada, Norikazu; Yao, Atsushi; Miyaji, Kohei; Nakanishi, Norifumi; Suzuki, Yumiko; Fujiwara, T.; Kuriyama, Takayuki

doi:10.1253/circj.cj-10-0671

Cited by 19 publications

(11 citation statements)

References 27 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase III multicenter open-label clinical trial of sildenafil in Japan examined data from 21 adult and pediatric patients with PAH. 54 At week 12, 6MWD increased by 84.2 m from baseline. Mean PAP, PVR, Borg dyspnea score, and plasma BNP also improved.…”

Section: Phosphodiesterase 5 Inhibitorsmentioning

confidence: 90%

See 1 more Smart Citation

Update on Pediatric Pulmonary Arterial Hypertension

Saji

2013

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Phosphodiesterase 5 Inhibitorsmentioning

confidence: 90%

“…Sildenafil 1 mg/kg/day was found to be effective and safe for pediatric IPAH. 54 During sildenafil therapy in another study, 6MWD increased from 278±114 to 443±107 m at 6 months (P=0.02) and to 432±156 m at 12 months (P=0.005). A plateau was reached between 6 and 12 months (P=0.48).…”

Section: Phosphodiesterase 5 Inhibitorsmentioning

confidence: 92%

Update on Pediatric Pulmonary Arterial Hypertension

Saji

2013

Circ J

Self Cite

View full text Add to dashboard Cite

“…In the clinical setting, it has been reported that bosentan and sildenafil are effective in treating PAH. 19- 21 The effect of ONO-1301 was equivalent to that of both those compounds. Considering that ONO-1301 has different actions, it shows promise for the treatment of PAH.…”

Section: Inhibitory Effect Of Ono-1301 On Thromboxane Synthesismentioning

confidence: 93%

Oral Administration of a Novel Long-Acting Prostacyclin Agonist With Thromboxane Synthase Inhibitory Activity for Pulmonary Arterial Hypertension

Nakamura

Nagaya

Obata

et al. 2013

Circ J

View full text Add to dashboard Cite

“…Pulmonary hypertension was defined by a resting mean PAP ≥ 25 mmHg during right heart catheterization (RHC) with a mean pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg (19).…”

Section: Subjectsmentioning

confidence: 99%

Acute Vasoreactivity Testing With Nicardipine in Patients With Pulmonary Arterial Hypertension

Saito¹,

Nakamura²,

Miyaji³

et al. 2012

J Pharmacol Sci

Self Cite

View full text Add to dashboard Cite

Abstract. Acute vasoreactivity testing for patients with pulmonary arterial hypertension (PAH) has been reported to be useful to identify patients with sustained beneficial response to oral calcium-channel blockers (CCBs), but there is a risk of exacerbation during the testing with oral CCBs. Therefore, we developed a testing method utilizing intravenous nicardipine, a short-acting CCB, and examined the safety and usefulness of acute vasoreactivity testing with nicardipine in PAH patients. Acute vasoreactivity testing with nicardipine was performed in 65 PAH patients. Nicardipine was administered by short-time continuous infusion (1 μg·kg ·min−1 for 5 min) followed by bolus injection (5 μg/kg). Hemodynamic responses were continuously measured using a right heart catheter. Acute responders were defined as patients who showed a decrease in mean pulmonary artery pressure of at least 10 mmHg to an absolute level below 40 mmHg with preserved or increased cardiac output. Two acute responders and sixty-three non-acute responders were identified. There was no hemodynamic instability requiring additional inotropic agents or death during the testing. Acute responders had good responses to long-term oral CCBs. The acute vasoreactivity testing with nicardipine might be safe and useful for identifying CCB responders in PAH patients.

show abstract

A Phase III, Multicenter, Collaborative, Open-Label Clinical Trial of Sildenafil in Japanese Patients With Pulmonary Arterial Hypertension

Cited by 19 publications

References 27 publications

Update on Pediatric Pulmonary Arterial Hypertension

Update on Pediatric Pulmonary Arterial Hypertension

Oral Administration of a Novel Long-Acting Prostacyclin Agonist With Thromboxane Synthase Inhibitory Activity for Pulmonary Arterial Hypertension

Acute Vasoreactivity Testing With Nicardipine in Patients With Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About